Rep. Kevin Hern (R-OK) Sells Novo Nordisk A (NVO) Stock

Kevin Hern, a Republican Congressman from Oklahoma's 1st district, sold shares of Novo Nordisk A/S (NYSE: NVO) on September 10, 2026. The transaction was valued between $1,001 and $15,000. He reported this trade on September 25, 2026.

Novo Nordisk, which specializes in diabetes care and other therapeutic areas, currently trades at $38.76. This price is near the lower end of its 52-week range, which spans from $35.12 to $64.16. The reported share price reflects a moderate market position compared to its recent performance.

Other Institutional Activity in Novo Nordisk A/S

Several institutional investors have been active with Novo Nordisk shares. Dodge & Cox Inc. grew its holdings by 1,063,356 shares, bringing its total to 20,397,110 shares worth about $789.8 million. LOOMIS SAYLES & CO L P increased its position by 1,577,465 shares, totaling 18,594,352 shares valued at approximately $720.0 million. Meanwhile, Franklin Resources, Inc. reduced its stake by 3,043,140 shares, ending with 13,041,109 shares valued at about $505.0 million. Additionally, Price (T.Rowe) Associates Inc. added 643,748 shares to reach a total of 11,704,719 shares worth about $453.2 million. Morgan Stanley also increased its holdings by 790,223 shares, totaling 11,659,869 shares valued at approximately $451.5 million.

Novo Nordisk A Stock Up 1.7%

As of the publication date, Novo Nordisk shares are trading at $38.76, close to their 50-day moving average of $42.85. This price reflects a challenging market phase for the stock, as it has underperformed compared to its previous highs.

Recent Earnings

In its latest earnings report, Novo Nordisk posted revenues of approximately $329.4 billion, showing a revenue growth rate of 2.1%. The net margin stood at 35.3%, with an impressive return on equity of 59.8%. The next earnings report is expected on November 4, 2026.

Analysts Set New Price Targets

On September 11, 2026, Morgan Stanley downgraded the stock to an "Underweight" rating with a price target of $40.0. This comes after BMO Capital maintained a "Market Perform" rating with a revised target of $40.0 on October 12, 2026. Overall, consensus among analysts suggests a hold recommendation with a mean target price of around $45.85 based on 12 opinions.

About Novo Nordisk A/S

Novo Nordisk A/S, based in Bagsvaerd, Denmark, focuses on the development and production of pharmaceutical products, particularly in diabetes and obesity care. The company also addresses rare diseases through its specialized product lines. This position in the healthcare sector is significant as it continues to navigate market fluctuations and regulatory changes.

Bottom Line

Investors should keep an eye on the upcoming earnings report on November 4, 2026, as well as any further trading activity from legislators like Kevin Hern. This 13F filing reflects positions as of September 10, 2026, and may not represent current holdings.